/
We are a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Currently, our commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need.
The business is unprofitable at the operating level (-34.25% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 370.2% YoY with margins expanding 837.0pp.
Negative free cash flow of -$18M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$37M
▲ +370.2% YoY
Net Income (TTM)
-$18M
▲ +76.6% YoY
Op. Margin
-37.05%
▲ +837.0pp YoY
ROIC
-36.72%
▲ +67.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$14M
▲ +71.1% YoY
Op. Cash Flow (TTM)
-$14M
▲ +71.1% YoY
Net Debt
-$19M
Net Cash Position
Cash & Equiv.
$21M
3Y CAGR: +57.9%
Continue Research